Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Akebia

Analysts Love These 2 Growth Stocks That Have Over 200% Upside Potential

Wall Street expects both of these biotech stocks to soar over 200% in the next 12 months.

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases

Here's a roundup of top developments in the biotech space over the last 24 hours:

The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact

The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact

Here's a roundup of top developments in the biotech space over the last 24 hours:

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Why Akebia Therapeutics Stock Is Soaring After Hours

Akebia Therapeutics Inc (NASDAQ: AKBA) shares are surging in Thursday's after-hours session after the company executed an agreement to terminate its Vadadustat collaboration and license agreements with Otsuka Pharmaceutical.

Why Are Akebia Therapeutics Shares Falling Today?

Akebia Therapeutics Inc (NASDAQ:AKBA) and Otsuka Holdings (OTC: OTSKY) separately announced to call for licensing and co-development agreement for vadadustat. Otsuka sent a written notice to Akebia on May 12 that the partnership had been terminated. Akebia said in an SEC filing filed Friday that the termination will go into effect in a year.…

See Why Does HC Wainwright Maintain Neutral On Akebia Stock

Akebia Therapeutics Inc (NASDAQ: AKBA) announced three poster presentations at the National Kidney Foundation (NKF) Spring Clinical Meetings 2022.

FDA Places Partial Hold On Vadadustat Pediatric Studies, Akebia Cuts Over 40% Staff

Battered after a surprising FDA rejection for its lead pipeline program last week, Akebia Therapeutics Inc (NASDAQ:AKBA) has layoffs that are now on the way. In a filing with the SEC, Akebia said the FDA issued a partial clinical hold on the drug's pediatric studies. As a result, Akebia will suspend all vadadustat studies…

inkl

Read news from The Economist, FT, and more,
with one subscription

FDA Rejects Akebia Therapeutics' Vadadustat For CKD-Associated Anemia

FDA Rejects Akebia Therapeutics' Vadadustat For CKD-Associated Anemia

The FDA has issued a complete response letter (CRL) to Akebia Therapeutics Inc's (NASDAQ:AKBA) marketing application (NDA) for vadadustat for anemia due to chronic kidney disease (CKD). Vadadustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. The FDA issues a CRL to indicate that the review cycle for an application is complete…

The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia

The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia

Here's a roundup of top developments in the biotech space over the last 24 hours:

Organisations

Food and Drug Administration

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

260,690 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play